Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest HER2/neu Stories

2013-12-11 08:24:22

Growth Opportunities May Exist in Tier 2 and Tier 3 Cities of China for Herceptin Amid Competition from Generic Brands, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists in China are embracing Roche's Herceptin as the targeted therapy for treating HER2+ gastric cancer in the first-line setting. The...

2013-12-05 08:29:39

Companion Algorithm ER (SP1) image analysis software clearance completes the company's breast diagnostic portfolio, providing physicians with the industry's only FDA-cleared testing package of five key breast biomarkers with their corresponding image analysis algorithms and digital read applications for cancer patients TUCSON, Ariz., Dec. 5, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and...

2013-11-25 12:27:04

PITTSBURGH, Nov. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche's Herceptin®, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name...

2013-11-18 08:30:23

Primary Efficacy Analysis Initiated for Phase II Study of Novel Immunotherapeutic WORCESTER, Mass. and TORONTO, Nov. 18, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary,...

2013-11-14 08:33:06

Findings further demonstrate the validity of a multiple-technology approach to tumor profiling for cancer patients IRVING, Texas, Nov. 14, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present five tumor profiling studies at the 2013 Annual Meeting of the Association for Molecular Pathology (AMP), held this week in Phoenix, Ariz. Results were obtained using Caris' comprehensive tumor profiling...

2013-11-08 08:27:57

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months ended September 30, 2013. Financial highlights for the third quarter include revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share. This compares to revenues of $5.3 million and a net loss of $20.0 million, or $0.18 per share, for the third quarter of 2012. (Logo:...

2013-11-07 12:27:09

Interviewed Payers Indicate that Budget Constraints May Also Drive Uptake of Trastuzumab Biosimilars over Branded Herceptin, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) currently prescribe Roche/Genentech's...

2013-10-28 23:01:00

Rockland Immunochemicals Inc. has received a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute, National Institutes of Health (NCI/NIH) to develop nanoprobes for in vivo imaging of cancer cells and tumors that express one of the three important cancer therapeutic targets: EGFR, Her2 and Mesothelin. This project is a joint collaboration between Rockland and Abzyme Therapeutics with in vivo imaging consultants from Yale University and the University...

2013-10-15 11:17:03

An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as two days after therapy administration, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. "The process of targeted drug development requires assays that measure drug target engagement and predict the response (or lack thereof) to treatment," said Alex...

2013-10-14 08:25:25

Prime Therapeutics analysis finds nearly 76 percent of patients taking Herceptin were treated in early stage breast cancer - important for predicting breast cancer future costs ST. PAUL, Minn., Oct. 14, 2013 /PRNewswire/ -- Expanded use of the common breast cancer drug Herceptin® (trastuzumab) can be tracked using pharmacy and medical administrative claims data, according to a new analysis by pharmacy benefit manager Prime Therapeutics LLC (Prime). Prime will be presenting the study...